)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Advanced Enzyme Technologies
Advanced Enzyme Technologies (ADVENZYMES) investor relations material
Advanced Enzyme Technologies Q1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 26/27 earnings summary12 Aug, 2026
Executive summary
Q1 FY27 consolidated revenue grew 2% year-on-year to INR 1,898 million, but declined 7% sequentially, with fundamentals remaining strong despite global disruptions.
EBITDA decreased 10% year-on-year and 19% sequentially, with margins at 27%.
PAT declined 5% year-on-year and 15% sequentially, with a PAT margin of 20%.
Board approved a buyback of up to INR 697 million at a ceiling price of INR 500 per share via open market.
Acquisition of the remaining 4.28% stake in JC Biotech, making it a wholly owned subsidiary.
Financial highlights
Q1 FY27 revenue was INR 1,898 million, up from INR 1,859.14 million in Q1 FY26, but down 7% sequentially due to sales reversals.
EBITDA for Q1 FY27 stood at INR 510 million, down 10% year-on-year and 19% quarter-on-quarter; EBITDA margin was 27%.
Profit after tax for Q1 FY27 was INR 386 million, a 5% year-on-year and 15% sequential decline; PAT margin at 20%.
R&D expenditure was INR 90 million, about 5% of revenue, consistent with prior year.
Q1 FY27 EPS at 3.31, down 7% year-on-year and 14% sequentially.
Outlook and guidance
Management expects to achieve double-digit revenue growth for FY27, with Q1 impacted by timing of sales recognition.
EBITDA margin is expected to recover to historical levels of around 30% for the full year.
Focus on expanding animal nutrition, bio-catalysis, probiotics, and baking solutions.
Plans to broaden geographical reach, strengthen distribution, and invest in R&D and strategic partnerships.
Anticipates improved cost trajectory and operational efficiency from Q2 onwards.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Advanced Enzyme Technologies
- FY26 saw record revenue, strong profit growth, and a proposed ₹1.35 per share final dividend.ADVENZYMES
Q4 25/26 - Q3 FY26 revenue up 2% YoY, PAT up 11%, with strong growth in animal and bioprocessing segments.ADVENZYMESQ3 25/26
- Q2 FY26 saw 26% YoY revenue growth, 33% EBITDA margin, and strong segment performance.ADVENZYMESQ2 25/26
- Q1 FY26 revenue up 20% to ₹1,859 million, with higher profits and robust segment growth.ADVENZYMESQ1 25/26
- Q2 FY25 revenue reached ₹1,461 million, net profit ₹334 million; H2 outlook remains strong.ADVENZYMESQ2 24/25
- Q1 FY25 saw 5% revenue and 19% PAT growth, strong US sales, and 12%-14% annual growth guidance.ADVENZYMESQ1 24/25
- FY25 revenue up 2% to INR 6,369 million, with strong growth in animal nutrition and specialized manufacturing.ADVENZYMESQ4 24/25
- Q3 FY25 saw revenue growth, strong margins, but lower profits due to impairment and legal costs.ADVENZYMESQ3 24/25
Next Advanced Enzyme Technologies earnings date
Q2 26/273 Nov, 2026
Advanced Enzyme Technologies
Next Advanced Enzyme Technologies earnings date
Q2 26/273 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Advanced Enzyme Technologies Limited is an India-based biotechnology company that manufactures and markets enzymes and probiotics. The company supplies products for industries including pharmaceuticals, food and beverage, animal nutrition, and textiles. It operates manufacturing and research facilities across India and internationally. Advanced Enzyme Technologies Limited is headquartered in Thane, India, and its shares are listed on the NSE.